0001415889-24-002714.txt : 20240205 0001415889-24-002714.hdr.sgml : 20240205 20240205190828 ACCESSION NUMBER: 0001415889-24-002714 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jooss Karin CENTRAL INDEX KEY: 0001754280 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38663 FILM NUMBER: 24597500 MAIL ADDRESS: STREET 1: C/O GRITSTONE ONCOLOGY, INC. STREET 2: 5858 HORTON STREET, SUITE 210 CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gritstone bio, Inc. CENTRAL INDEX KEY: 0001656634 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5959 HORTON STREET, SUITE 300 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 871-6100 MAIL ADDRESS: STREET 1: 5959 HORTON STREET, SUITE 300 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: Gritstone Oncology, Inc. DATE OF NAME CHANGE: 20151023 4 1 form4-02062024_120216.xml X0508 4 2024-02-01 0001656634 Gritstone bio, Inc. GRTS 0001754280 Jooss Karin C/O GRITSTONE BIO, INC. 5959 HORTON STREET, SUITE 300 EMERYVILLE CA 94608 false true false false SEE REMARKS 0 Common Stock 2024-02-01 4 A 0 40000 0 A 648851 D Stock Option (Right to Buy) 2.46 2024-02-01 4 A 0 235000 0 A 2034-01-31 Common Stock 235000 235000 D Represents Restricted Stock Units ("RSUs") of which 1/2 vests on the first anniversary of the grant date, with the remainder of grant vesting on the second anniversary of the grant date, subject to the continued service of the Reporting Person on each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Includes 271,467 RSUs which are subject to vesting. The option vests as to 1/24th of the total grant monthly beginning February 1, 2024 until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. EVP, Head of Research and Development /s/ Vassiliki Economides, Attorney-in-Fact for Karin Jooss 2024-02-05